Eagle Pharmaceuticals, Inc. Reports Second Quarter 2015 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- S&P 500, Nasdaq rise in choppy trading as tech steadies, Micron results in focus
- Brent hits lowest since before start of Iran war on expectations of smoother oil flows via Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- JPMorgan raises S&P 500 target to 7,800, says earnings revision ’unprecedented’
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Eagle Pharmaceuticals (EGRX) PT Raised to $120 at Piper Jaffray
August 12, 2015 8:28 AM EDTPiper Jaffray analyst David Amsellem reiterated an Overweight rating and lifted his price target on Eagle Pharmaceuticals (NASDAQ: EGRX) to $120.00 (from $119.00) following the company's Q2 update.
commented, "This morning, Eagle reported net results per share of ($0.53) on revenues of $6M. Management provided... More
Eagle Pharmaceuticals (EGRX) Tops Q2 EPS by 4c
August 11, 2015 7:48 AM EDTEagle Pharmaceuticals (NASDAQ: EGRX) reported Q2 EPS of ($0.53), $0.04 better than the analyst estimate of ($0.57). Revenue for the quarter came in at $6 million versus the consensus estimate of $4.7 million.
For earnings history and earnings-related data on Eagle Pharmaceuticals (EGRX) click here.
... More